Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 7/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.45 |
| ▸ | BCR | P11274 | 3/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 3/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640749 | 0.89 | ABL1 (0.47) | SLC2A1EGFRBRAFABL1BCR | |
| SCHEMBL1640284 | 0.86 | ABL1 (0.50) | SLC2A1EGFRBRAFABL1BCR | |
| SCHEMBL1642021 | 0.82 | ABL1 (0.51) | SLC2A1EGFRBRAFABL1BCR | |
| SCHEMBL1641134 | 0.81 | SLC2A1 (0.63) | SLC2A1EGFRBRAFABL1BCR | |
| SCHEMBL1641758 | 0.78 | AURKA (0.59) | SLC2A1EGFRBRAFJAK3IGF1R | |
| SCHEMBL1643563 | 0.78 | EGFR (0.47) | SLC2A1EGFRBRAFABL1BCR | |
| SCHEMBL1640515 | 0.77 | SLC2A1 (0.55) | SLC2A1EGFRBRAFABL1BCR | |
| SCHEMBL1641789 | 0.77 | SLC2A1 (0.56) | SLC2A1EGFRBRAFBTKIGF1R | |
| SCHEMBL12766952 | 0.77 | BRAF (0.70) | SLC2A1EGFRBRAFIGF1RERBB2 | |
| SCHEMBL1640522 | 0.76 | BRAF (0.61) | SLC2A1EGFRBRAFJAK3IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| WO-2009076140-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | PDXK, MAP3K1, MAP4K2 | SLC2A1 2698/4885EGFR 478/4885BRAF 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.